Jennerex appoints new board member
This article was originally published in Scrip
Jennerex, a US biotechnology company which develops oncology products, has appointed Dr Hoyoung Huh to its board of directors. Dr Huh serves as chairman of the board of BiPar Sciences, a clinical-stage cancer drug development company, which is a wholly owned subsidiary of Sanofi-Aventis, for which he led the $500 million merger last year (scripnews.com, April 16th, 2009). Dr Huh is also chairman of the board of Epizyme, and was previously chief operating officer at Nektar Therapeutics.